×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALKS – alkermes plc - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALKS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/17
04:00 pm
alks
Alkermes to Report First Quarter Financial Results on May 1, 2025
Neutral
Report
Alkermes to Report First Quarter Financial Results on May 1, 2025
4/17
04:00 pm
alks
Alkermes to Report First Quarter Financial Results on May 1, 2025
Neutral
Report
Alkermes to Report First Quarter Financial Results on May 1, 2025
4/2
04:00 pm
alks
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
Medium
Report
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
4/2
04:00 pm
alks
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
Medium
Report
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
4/1
07:22 am
alks
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia [Yahoo! Finance]
Low
Report
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia [Yahoo! Finance]
4/1
07:00 am
alks
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
Neutral
Report
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
4/1
07:00 am
alks
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
Neutral
Report
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
3/27
08:15 am
alks
Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $40.00 to $52.00. They now have a "buy" rating on the stock.
Low
Report
Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $40.00 to $52.00. They now have a "buy" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
2/12/2025
07:00 am
alks
alkermes plc - ordinary shares
BEAT
Report
3.4%
alkermes plc - ordinary shares
2/12/2025
07:00 am
alks
alkermes plc - ordinary shares
BEAT
Report
1.5%
alkermes plc - ordinary shares
2/12/2025
07:00 am
alks
alkermes plc - ordinary shares
BEAT
Report
3.7%
alkermes plc - ordinary shares
2/12/2025
07:00 am
alks
alkermes plc - ordinary shares
BEAT
Report
1.7%
alkermes plc - ordinary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/16
07:54 am
alks
Form 8-K Alkermes plc. For: Apr 14
Medium
Report
Form 8-K Alkermes plc. For: Apr 14
4/14
05:18 pm
alks
Form 4 Alkermes plc. For: Apr 11 Filed by: Lurker Nancy
Low
Report
Form 4 Alkermes plc. For: Apr 11 Filed by: Lurker Nancy
4/7
04:59 pm
alks
Form ARS Alkermes plc. For: Dec 31
Medium
Report
Form ARS Alkermes plc. For: Dec 31
4/7
04:48 pm
alks
Form DEF 14A Alkermes plc. For: May 21
Medium
Report
Form DEF 14A Alkermes plc. For: May 21
3/28
05:09 pm
alks
Form PRE 14A Alkermes plc. For: May 21
Low
Report
Form PRE 14A Alkermes plc. For: May 21
2/28
05:19 pm
alks
Form 4 Alkermes plc. For: Feb 26 Filed by: Parisi Samuel Joseph
Low
Report
Form 4 Alkermes plc. For: Feb 26 Filed by: Parisi Samuel Joseph
2/28
05:18 pm
alks
Form 4 Alkermes plc. For: Feb 26 Filed by: Nichols Christian Todd
Low
Report
Form 4 Alkermes plc. For: Feb 26 Filed by: Nichols Christian Todd
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/19
Alkermes to Present at the 9th Annual SVB Leerink Global Healthcare Conference
9.4%
3/13 Alkermes Plc (NASDAQ: ALKS) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 8.8%
7/29 Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute 7.5%
4/3 Form 4 Alkermes plc. For: Apr 02 Filed by: POPS RICHARD F 7.3%
2/18 Form 4 Alkermes plc. For: Feb 16 Filed by: LANDINE MICHAEL J 7.2%
7/30 Form 8-K Alkermes plc. For: Jul 26 6.0%
2/5 Form SC 13G/A Alkermes plc. Filed by: BlackRock Inc. 5.1%
12/4 Form CT ORDER Alkermes plc. 4.7%
9/10 Alkermes (ALKS) Investor Presentation - Slideshow [Seeking Alpha] 4.7%
10/23 Alkermes Plc (NASDAQ: ALKS) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $23.00 price target on the stock, down previously from $25.00. 4.6%
3/13 Alkermes Plc (NASDAQ: ALKS) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 8.8%
7/29 Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute 7.5%
4/3 Form 4 Alkermes plc. For: Apr 02 Filed by: POPS RICHARD F 7.3%
2/18 Form 4 Alkermes plc. For: Feb 16 Filed by: LANDINE MICHAEL J 7.2%
7/30 Form 8-K Alkermes plc. For: Jul 26 6.0%
2/5 Form SC 13G/A Alkermes plc. Filed by: BlackRock Inc. 5.1%
12/4 Form CT ORDER Alkermes plc. 4.7%
9/10 Alkermes (ALKS) Investor Presentation - Slideshow [Seeking Alpha] 4.7%
10/23 Alkermes Plc (NASDAQ: ALKS) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $23.00 price target on the stock, down previously from $25.00. 4.6%
TOP News Decliners
4/29
Form 10-Q Alkermes plc. For: Mar 31
-15.2%
7/25 Alkermes Plc Reports Second Quarter 2019 Financial Results -12.6%
2/13 Form 10-K Alkermes plc. For: Dec 31 -8.5%
3/19 Form 4 Alkermes plc. For: Mar 19 Filed by: POPS RICHARD F -7.3%
4/30 Alkermes Plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock, down previously from $25.00. -6.9%
9/23 Form 4 Alkermes plc. For: Sep 19 Filed by: POPS RICHARD F -4.7%
10/23 Alkermes PLC (ALKS) Q3 2019 Earnings Call Transcript [The Motley Fool] -4.4%
5/13 Alkermes to Showcase Leadership in Schizophrenia With New Data Presentations at Upcoming Scientific Conferences -4.4%
7/18 Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results -4.2%
5/22 Form 8-K Alkermes plc. For: May 22 -4.0%
7/25 Alkermes Plc Reports Second Quarter 2019 Financial Results -12.6%
2/13 Form 10-K Alkermes plc. For: Dec 31 -8.5%
3/19 Form 4 Alkermes plc. For: Mar 19 Filed by: POPS RICHARD F -7.3%
4/30 Alkermes Plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock, down previously from $25.00. -6.9%
9/23 Form 4 Alkermes plc. For: Sep 19 Filed by: POPS RICHARD F -4.7%
10/23 Alkermes PLC (ALKS) Q3 2019 Earnings Call Transcript [The Motley Fool] -4.4%
5/13 Alkermes to Showcase Leadership in Schizophrenia With New Data Presentations at Upcoming Scientific Conferences -4.4%
7/18 Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results -4.2%
5/22 Form 8-K Alkermes plc. For: May 22 -4.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: